Anticancer activities of a benzimidazole compound through sirtuin inhibition in colorectal cancer

Yi Jer Tan; Yeuan Ting Lee; Keng Yoon Yeong; Sven H. Petersen; Koji Kono; Soo Choon Tan; Chern Ein Oon

doi:10.4155/fmc-2018-0052

Anticancer activities of a benzimidazole compound through sirtuin inhibition in colorectal cancer

Yi Jer Tan, Yeuan Ting Lee, Keng Yoon Yeong, Sven H. Petersen, Koji Kono, Soo Choon Tan, Chern Ein Oon

Malaysia Sch of Science

Research output: Contribution to journal › Article › Research › peer-review

31 Citations (Scopus)

Abstract

Aim: This study aims to investigate the mode of action of a novel sirtuin inhibitor (BZD9L1) and its associated molecular pathways in colorectal cancer (CRC) cells. Materials & methods: BZD9L1 was tested against metastatic CRC cell lines to evaluate cytotoxicity, cell cycle and apoptosis, senescence, apoptosis related genes and protein expressions, as well as effect against major cancer signaling pathways. Results & conclusion: BZD9L1 reduced the viability, cell migration and colony forming ability of both HCT 116 and HT-29 metastatic CRC cell lines through apoptosis. BZD9L1 regulated major cancer pathways differently in CRC with different mutation profiles. BZD9L1 exhibited anticancer activities as a cytotoxic drug in CRC and as a promising therapeutic strategy in CRC treatment.

Original language	English
Pages (from-to)	2039-2057
Number of pages	19
Journal	Future Medicinal Chemistry
Volume	10
Issue number	17
DOIs	https://doi.org/10.4155/fmc-2018-0052
Publication status	Published - Sept 2018

Keywords

BZD9L1
colorectal cancer
sirtuin
targeted therapy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.4155/fmc-2018-0052

Cite this

@article{1dab4bec40c34f9cb437bb8b5b88f919,

title = "Anticancer activities of a benzimidazole compound through sirtuin inhibition in colorectal cancer",

abstract = "Aim: This study aims to investigate the mode of action of a novel sirtuin inhibitor (BZD9L1) and its associated molecular pathways in colorectal cancer (CRC) cells. Materials \& methods: BZD9L1 was tested against metastatic CRC cell lines to evaluate cytotoxicity, cell cycle and apoptosis, senescence, apoptosis related genes and protein expressions, as well as effect against major cancer signaling pathways. Results \& conclusion: BZD9L1 reduced the viability, cell migration and colony forming ability of both HCT 116 and HT-29 metastatic CRC cell lines through apoptosis. BZD9L1 regulated major cancer pathways differently in CRC with different mutation profiles. BZD9L1 exhibited anticancer activities as a cytotoxic drug in CRC and as a promising therapeutic strategy in CRC treatment.",

keywords = "BZD9L1, colorectal cancer, sirtuin, targeted therapy",

author = "Tan, \{Yi Jer\} and Lee, \{Yeuan Ting\} and Yeong, \{Keng Yoon\} and Petersen, \{Sven H.\} and Koji Kono and Tan, \{Soo Choon\} and Oon, \{Chern Ein\}",

note = "Funding Information: This project was funded by Ranjeet Bhagwan Singh Medical Research Grant (304/CIPPM/650708/K105) and EScience Fund (MOSTI) (305/CIPPM/613620). Yeuan Ting Lee was supported by USM graduate assistant fellowship. The authors would also like to thank Warren Lee Xian Liang for technical advice on western blot.The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. Publisher Copyright: {\textcopyright} 2018 2018 Newlands Press. Copyright: Copyright 2019 Elsevier B.V., All rights reserved.",

year = "2018",

month = sep,

doi = "10.4155/fmc-2018-0052",

language = "English",

volume = "10",

pages = "2039--2057",

journal = "Future Medicinal Chemistry",

issn = "1756-8919",

publisher = "Future Science Ltd.",

number = "17",

}

TY - JOUR

T1 - Anticancer activities of a benzimidazole compound through sirtuin inhibition in colorectal cancer

AU - Tan, Yi Jer

AU - Lee, Yeuan Ting

AU - Yeong, Keng Yoon

AU - Petersen, Sven H.

AU - Kono, Koji

AU - Tan, Soo Choon

AU - Oon, Chern Ein

N1 - Funding Information: This project was funded by Ranjeet Bhagwan Singh Medical Research Grant (304/CIPPM/650708/K105) and EScience Fund (MOSTI) (305/CIPPM/613620). Yeuan Ting Lee was supported by USM graduate assistant fellowship. The authors would also like to thank Warren Lee Xian Liang for technical advice on western blot.The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. Publisher Copyright: © 2018 2018 Newlands Press. Copyright: Copyright 2019 Elsevier B.V., All rights reserved.

PY - 2018/9

Y1 - 2018/9

N2 - Aim: This study aims to investigate the mode of action of a novel sirtuin inhibitor (BZD9L1) and its associated molecular pathways in colorectal cancer (CRC) cells. Materials & methods: BZD9L1 was tested against metastatic CRC cell lines to evaluate cytotoxicity, cell cycle and apoptosis, senescence, apoptosis related genes and protein expressions, as well as effect against major cancer signaling pathways. Results & conclusion: BZD9L1 reduced the viability, cell migration and colony forming ability of both HCT 116 and HT-29 metastatic CRC cell lines through apoptosis. BZD9L1 regulated major cancer pathways differently in CRC with different mutation profiles. BZD9L1 exhibited anticancer activities as a cytotoxic drug in CRC and as a promising therapeutic strategy in CRC treatment.

AB - Aim: This study aims to investigate the mode of action of a novel sirtuin inhibitor (BZD9L1) and its associated molecular pathways in colorectal cancer (CRC) cells. Materials & methods: BZD9L1 was tested against metastatic CRC cell lines to evaluate cytotoxicity, cell cycle and apoptosis, senescence, apoptosis related genes and protein expressions, as well as effect against major cancer signaling pathways. Results & conclusion: BZD9L1 reduced the viability, cell migration and colony forming ability of both HCT 116 and HT-29 metastatic CRC cell lines through apoptosis. BZD9L1 regulated major cancer pathways differently in CRC with different mutation profiles. BZD9L1 exhibited anticancer activities as a cytotoxic drug in CRC and as a promising therapeutic strategy in CRC treatment.

KW - BZD9L1

KW - colorectal cancer

KW - sirtuin

KW - targeted therapy

UR - https://www.scopus.com/pages/publications/85052685986

U2 - 10.4155/fmc-2018-0052

DO - 10.4155/fmc-2018-0052

M3 - Article

C2 - 30066578

AN - SCOPUS:85052685986

SN - 1756-8919

VL - 10

SP - 2039

EP - 2057

JO - Future Medicinal Chemistry

JF - Future Medicinal Chemistry

IS - 17

ER -

Anticancer activities of a benzimidazole compound through sirtuin inhibition in colorectal cancer

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Cite this